Aptose Biosciences (NASDAQ:APTO) Shares Up 7%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS)’s share price shot up 7% on Wednesday . The company traded as high as $2.20 and last traded at $2.15. 654,522 shares traded hands during trading, an increase of 125% from the average session volume of 290,342 shares. The stock had previously closed at $2.01.

A number of brokerages have weighed in on APTO. Roth Capital reissued a “buy” rating on shares of Aptose Biosciences in a research report on Thursday, May 23rd. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Monday, May 13th. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Finally, Royal Bank of Canada began coverage on Aptose Biosciences in a research report on Friday, March 1st. They set an “outperform” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Aptose Biosciences presently has an average rating of “Buy” and an average target price of $5.75.

The firm has a market capitalization of $87.09 million, a PE ratio of -2.50 and a beta of 1.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.93 and a quick ratio of 5.93.



Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. On average, equities analysts forecast that Aptose Biosciences Inc. will post -0.61 earnings per share for the current fiscal year.

In other news, Director Erich Platzer sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total transaction of $43,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have bought 27,500 shares of company stock valued at $51,300. Corporate insiders own 7.34% of the company’s stock.

Large investors have recently modified their holdings of the company. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Aptose Biosciences by 37.3% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 78,829 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 21,400 shares during the period. Noven Financial Group Inc. bought a new stake in shares of Aptose Biosciences during the fourth quarter worth approximately $27,000. Virtu Financial LLC bought a new stake in shares of Aptose Biosciences during the first quarter worth approximately $198,000. Boston Advisors LLC bought a new stake in shares of Aptose Biosciences during the first quarter worth approximately $36,000. Finally, Geode Capital Management LLC bought a new stake in shares of Aptose Biosciences during the fourth quarter worth approximately $33,000. Institutional investors own 7.53% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://dakotafinancialnews.com/2019/06/13/aptose-biosciences-nasdaqapto-shares-up-7.html.

About Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading: What is Liquidity?

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.